Published in J Cell Biol on May 25, 2009
Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet (2010) 4.26
ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res (2010) 3.46
Nuclear bodies: random aggregates of sticky proteins or crucibles of macromolecular assembly? Dev Cell (2009) 2.29
Telomeric armor: the layers of end protection. J Cell Sci (2009) 0.95
PML body meets telomere: the beginning of an ALTernate ending? Nucleus (2012) 0.94
Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat Struct Mol Biol (2015) 0.92
HP1-mediated formation of alternative lengthening of telomeres-associated PML bodies requires HIRA but not ASF1a. PLoS One (2011) 0.86
Essential role of the Cdk2 activator RingoA in meiotic telomere tethering to the nuclear envelope. Nat Commun (2016) 0.85
Role of Cdk1 in DNA damage-induced G1 checkpoint abrogation by the human papillomavirus E7 oncogene. Cell Cycle (2014) 0.82
p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem (2010) 0.81
Modulation of telomeres in alternative lengthening of telomeres type I like human cells by the expression of werner protein and telomerase. J Oncol (2012) 0.80
The telomere-associated homeobox-containing protein TAH1/HMBOX1 participates in telomere maintenance in ALT cells. J Cell Sci (2013) 0.79
Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences. Cell Death Dis (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell (1985) 24.17
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature (2001) 19.67
A survey of telomerase activity in human cancer. Eur J Cancer (1997) 10.84
Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci (2001) 6.66
Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med (1997) 6.55
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res (1994) 6.16
Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J (1995) 6.03
Protection of mammalian telomeres. Oncogene (2002) 5.38
Telomere maintenance by recombination in human cells. Nat Genet (2000) 5.14
Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science (1997) 4.97
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell (2005) 4.83
DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol (2006) 4.38
The HP1 protein family: getting a grip on chromatin. Curr Opin Genet Dev (2000) 4.34
Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat Genet (2000) 4.30
Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res (1999) 4.24
The epigenetic regulation of mammalian telomeres. Nat Rev Genet (2007) 3.82
Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet (2003) 3.64
Alternative lengthening of telomeres in mammalian cells. Oncogene (2002) 3.48
PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 3.35
Telomere dynamics in an immortal human cell line. EMBO J (1994) 3.22
Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature (1994) 3.21
The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat Struct Mol Biol (2007) 3.15
A conserved Mis12 centromere complex is linked to heterochromatic HP1 and outer kinetochore protein Zwint-1. Nat Cell Biol (2004) 3.04
ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol Cell (2003) 3.01
PCNA is a cofactor for Cdt1 degradation by CUL4/DDB1-mediated N-terminal ubiquitination. J Biol Chem (2006) 2.96
The KAP1 corepressor functions to coordinate the assembly of de novo HP1-demarcated microenvironments of heterochromatin required for KRAB zinc finger protein-mediated transcriptional repression. Mol Cell Biol (2006) 2.93
p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta (2000) 2.81
Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc Natl Acad Sci U S A (1998) 2.59
Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene (1999) 2.34
Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 53BP1 and functions in the S-phase checkpoint. Genes Dev (2004) 2.33
Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol (2005) 2.27
Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol (2001) 1.99
Visualizing telomere dynamics in living mammalian cells using PNA probes. EMBO J (2003) 1.99
The Saccharomyces cerevisiae WRN homolog Sgs1p participates in telomere maintenance in cells lacking telomerase. EMBO J (2001) 1.99
Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci U S A (1997) 1.96
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
The first molecular details of ALT in human tumor cells. Hum Mol Genet (2005) 1.93
p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene (1999) 1.90
Telomere maintenance requires the RAD51D recombination/repair protein. Cell (2004) 1.89
Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol (1995) 1.85
Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. EMBO Rep (2002) 1.79
Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A (2002) 1.72
NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J Biol Chem (2000) 1.71
The role of senescence and immortalization in carcinogenesis. Carcinogenesis (2000) 1.67
Nuclear structure in normal and Bloom syndrome cells. Proc Natl Acad Sci U S A (2000) 1.60
Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J Biol Chem (2007) 1.55
The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. Hum Mol Genet (2002) 1.53
Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body. J Biol Chem (2004) 1.49
Human heterochromatin protein 1 isoforms HP1(Hsalpha) and HP1(Hsbeta) interfere with hTERT-telomere interactions and correlate with changes in cell growth and response to ionizing radiation. Mol Cell Biol (2003) 1.44
Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol Cell Biol (2005) 1.44
Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene (2007) 1.42
The Drosophila Mre11/Rad50 complex is required to prevent both telomeric fusion and chromosome breakage. Curr Biol (2004) 1.38
Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. Cancer Res (2003) 1.36
Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res (2005) 1.35
DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA. Cancer Res (2007) 1.34
ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci (2000) 1.30
PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase. J Cell Sci (2006) 1.30
A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene (2005) 1.30
Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene (1999) 1.27
Cellular senescence and chromatin structure. Chromosoma (2007) 1.26
Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. Cell Growth Differ (1998) 1.26
Higher-order nuclear organization in growth arrest of human mammary epithelial cells: a novel role for telomere-associated protein TIN2. J Cell Sci (2005) 1.17
SALL1, the gene mutated in Townes-Brocks syndrome, encodes a transcriptional repressor which interacts with TRF1/PIN2 and localizes to pericentromeric heterochromatin. Hum Mol Genet (2001) 1.14
A novel telomere structure in a human alternative lengthening of telomeres cell line. Cancer Res (2005) 1.09
Y-box factor YB1 controls p53 apoptotic function. Oncogene (2005) 1.08
Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit. Oncogene (2002) 1.07
hnRNP A2, a potential ssDNA/RNA molecular adapter at the telomere. Nucleic Acids Res (2005) 1.06
Germ-line splicing mutation of the p53 gene in a cancer-prone family. Cell Growth Differ (1992) 1.01
Spatiotemporal dynamics of p21CDKN1A protein recruitment to DNA-damage sites and interaction with proliferating cell nuclear antigen. J Cell Sci (2006) 0.95
Altered distribution of the promyelocytic leukemia-associated protein is associated with cellular senescence. Cell Growth Differ (1997) 0.95
In vitro transformation of Li-Fraumeni syndrome fibroblasts by SV40 large T antigen mutants. Oncogene (1994) 0.95
p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance. Mol Cell Biol (2004) 0.93
Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA. J Cell Biol (2007) 0.92
Expression and functional analysis of three isoforms of human heterochromatin-associated protein HP1 in Drosophila. Chromosoma (2001) 0.90
Overexpression of the p21 sdi1 gene induces senescence-like state in human cancer cells: implication for senescence-directed molecular therapy for cancer. Cell Death Differ (1999) 0.88
Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. Cancer Res (2006) 0.87
Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells. Anticancer Res (2000) 0.81
Chromosomal localization of human homologs of the Drosophila heterochromatin protein 1 (HP1) gene. Mamm Genome (1993) 0.79
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet (2010) 4.26
Protein composition of catalytically active human telomerase from immortal cells. Science (2007) 3.53
Alternative lengthening of telomeres in mammalian cells. Oncogene (2002) 3.48
Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer (2010) 3.04
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet (2012) 2.63
DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol (2009) 2.35
Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat Struct Mol Biol (2009) 2.08
Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res (2004) 1.99
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
The first molecular details of ALT in human tumor cells. Hum Mol Genet (2005) 1.93
Control of telomere length by a trimming mechanism that involves generation of t-circles. EMBO J (2009) 1.85
Telomere uncapping and alternative lengthening of telomeres. Mech Ageing Dev (2007) 1.68
Human POT1 facilitates telomere elongation by telomerase. Curr Biol (2003) 1.64
Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Lett (2010) 1.64
Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle (2005) 1.59
Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acids Res (2009) 1.55
DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology (2009) 1.55
Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J Biol Chem (2007) 1.55
Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep (2011) 1.45
Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44
Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol Cell Biol (2005) 1.44
Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer (2006) 1.42
YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J (2013) 1.38
Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res (2005) 1.35
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med (2010) 1.35
DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA. Cancer Res (2007) 1.34
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol (2010) 1.32
Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells. Nat Genet (2002) 1.31
Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res (2002) 1.29
Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci (2008) 1.28
Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res (2011) 1.25
Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. Hum Mol Genet (2009) 1.20
Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One (2011) 1.20
A sensitive direct human telomerase activity assay. Nat Methods (2008) 1.19
Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res (2002) 1.18
Telomere maintenance and cancer -- look, no telomerase. Nat Rev Cancer (2002) 1.17
Normal mammalian cells negatively regulate telomere length by telomere trimming. Hum Mol Genet (2011) 1.16
Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther (2005) 1.15
Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. Cancer Res (2007) 1.15
Overexpressed mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts. Exp Cell Res (2003) 1.12
Y-box factor YB1 controls p53 apoptotic function. Oncogene (2005) 1.08
Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit. Oncogene (2002) 1.07
hnRNP A2, a potential ssDNA/RNA molecular adapter at the telomere. Nucleic Acids Res (2005) 1.06
Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood (2011) 1.05
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res (2006) 1.05
Alternative lengthening of telomeres in normal mammalian somatic cells. Genes Dev (2013) 1.04
YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst (2011) 1.04
Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres. PLoS One (2012) 1.04
STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res (2012) 1.02
Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells. J Cell Biol (2012) 1.02
Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res (2008) 1.02
The dynamin inhibitors MiTMAB and OcTMAB induce cytokinesis failure and inhibit cell proliferation in human cancer cells. Mol Cancer Ther (2010) 1.01
Telomere elongation involves intra-molecular DNA replication in cells utilizing alternative lengthening of telomeres. Hum Mol Genet (2008) 1.01
Nuclear localization of Y-box factor YB1 requires wild-type p53. Oncogene (2003) 1.01
Cancer. Cancer and telomeres--an ALTernative to telomerase. Science (2012) 1.00
Alternative lengthening of telomeres: remodeling the telomere architecture. Front Oncol (2013) 1.00
CARF is a novel protein that cooperates with mouse p19ARF (human p14ARF) in activating p53. J Biol Chem (2002) 1.00
MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3' untranslated region. Nucleic Acids Res (2011) 0.99
The murine stanniocalcin 1 gene is not essential for growth and development. Mol Cell Biol (2005) 0.98
PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Res (2008) 0.98
The murine stanniocalcin 2 gene is a negative regulator of postnatal growth. Endocrinology (2008) 0.98
The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem (2003) 0.98
The mesenchymal architecture of the cranial mesoderm of mouse embryos is disrupted by the loss of Twist1 function. Dev Biol (2012) 0.97
The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene (2003) 0.95
The role of telomere trimming in normal telomere length dynamics. Cell Cycle (2012) 0.94
Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Res (2012) 0.92
Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol (2002) 0.92
Alterations in the p16(INK4a) and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts. Oncogene (2004) 0.90
A rapid and optimization-free procedure allows the in vivo detection of subtle cell cycle and ploidy alterations in tissues by flow cytometry. Cell Cycle (2010) 0.89
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One (2011) 0.88
Does Δ133p53 isoform trigger inflammation and autoimmunity? Cell Cycle (2012) 0.87
Enhanced isolation of fibroblasts from human skin explants. Biotechniques (2012) 0.86
HP1-mediated formation of alternative lengthening of telomeres-associated PML bodies requires HIRA but not ASF1a. PLoS One (2011) 0.86
Telomerase activity in pleural malignant mesotheliomas. Lung Cancer (2011) 0.86
Rhodacyanine dye MKT-077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo. Cancer Res (2002) 0.86
Amplification of telomerase reverse transcriptase gene in human mammary epithelial cells with limiting telomerase RNA expression levels. Cancer Res (2008) 0.84
Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome. Hum Mol Genet (2005) 0.83
Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS One (2011) 0.83
Dynamin inhibitors induce caspase-mediated apoptosis following cytokinesis failure in human cancer cells and this is blocked by Bcl-2 overexpression. Mol Cancer (2011) 0.82
STC1 expression is associated with tumor growth and metastasis in breast cancer. Clin Exp Metastasis (2014) 0.82
A major functional difference between the mouse and human ARF tumor suppressor proteins. J Biol Chem (2002) 0.80
Telomere extension by telomerase and ALT generates variant repeats by mechanistically distinct processes. Nucleic Acids Res (2013) 0.80
Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms. Hum Genet (2009) 0.80
Extreme telomere length dimorphism in the Tasmanian devil and related marsupials suggests parental control of telomere length. PLoS One (2012) 0.79
Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21(WAF1/CIP1). J Cell Sci (2009) 0.78